BrightGene Bio Medical Technology C (688166) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of BrightGene Bio Medical Technology C stock ¥2.75, price ¥26.53, that is 89.6% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
BrightGene Bio Medical Technology C
688166 · SHGFar too expensive (fair value 90% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 18, 2026.
How to read this chart
60‑month range ¥17.39 – ¥116.49 · fair‑value band ¥2.06 – ¥3.44 · the ¥26.53 price screens above the ¥2.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 18, 2026.
Every Wednesday you see whether BrightGene Bio Medical Technology C is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally.
Show moreShow less
The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development.
It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others.
In addition, the company is involved in technology research and development; transfer of biomedical products; import, export, wholesale, and retail of medicines; production and operation of medical devices; and technical services.
BrightGene Bio-Medical Technology Co., Ltd. was founded in 2001 and is based in Suzhou, China.
Stock analysis
BrightGene Bio Medical Technology C (688166) currently trades at ¥26.53, while our model-based Fair Value estimate is ¥2.75, 90% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of ¥3.88 per share, and 0 of the 16 models we run sit above the ¥26.53 price.
Bear case: the Economic Profit group reads lowest at ¥2.28, and 16 of the 16 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥2.06 (bear) to ¥3.44 (bull), the price of ¥26.53 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
BrightGene Bio Medical Technology C reported revenue of 1.2B CNY in FY2025 versus 1.1B CNY in FY2021, a compound +3.8%/yr. Reported net income was 54.5M CNY in FY2025, compounding −31.2%/yr from FY2021.
Key figures
Market cap 11.8B CNY (≈ $1.8B) Small · P/E ratio 115.3 · P/S ratio 8.62 · EPS (TTM) ¥0.2300 · Dividend yield 0.1% · Net margin 7.1% · Return on equity 3.3% · Return on assets (EBIT) 5.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).
What moves the price
The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −90%, 688166 screens richer than that median.
Fair Value models
All 16 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare BrightGene Bio Medical Technology C with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- Stock screener with 62 metrics
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $945.53 | $1,275 | +35% | vs 688166 |
| Samsung Biologics Co 207940 | 1,366,000 KRW | 1,502,600 KRW | +10% | vs 688166 |
| Vertex Pharmaceuticals Incorporated VRTX | $536.45 | $587.62 | +10% | vs 688166 |
| argenx SE ARGX | $941.25 | $908.40 | −3% | vs 688166 |
| CSL Limited CSL | A$199.85 | A$186.49 | −7% | vs 688166 |
| Moderna, Inc MRNA | $196.79 | $135.64 | −31% | vs 688166 |
| BeOne Medicines AG 6160 | HK$244.80 | HK$152.92 | −38% | vs 688166 |
| Revolution Medicines, Inc RVMD | $159.82 | $88.78 | −44% | vs 688166 |
| Celltrion, Inc 068270 | 207,500 KRW | 74,945 KRW | −64% | vs 688166 |
| Royalty Pharma plc RPRX | $68.67 | $19.01 | −72% | vs 688166 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is BrightGene Bio Medical Technology C (688166) overvalued or undervalued?
What is the fair value of 688166?
What is the quality score of 688166?
What is the price target for BrightGene Bio Medical Technology C (688166)?
What is the BrightGene Bio Medical Technology C stock forecast for 2026?
What is the revenue of BrightGene Bio Medical Technology C (688166)?
Does BrightGene Bio Medical Technology C pay a dividend?
How much is the dividend of BrightGene Bio Medical Technology C (688166) and when is the ex-dividend date?
What is the intrinsic value of BrightGene Bio Medical Technology C (688166)?
Is BrightGene Bio Medical Technology C stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 688166?
How much is BrightGene Bio Medical Technology C worth?
What do the bullish and bearish scenarios say about 688166?
What is the P/E ratio of 688166?
How solid is the balance sheet of BrightGene Bio Medical Technology C (688166)?
How far is 688166 from its 52-week high?
Which stocks are comparable to BrightGene Bio Medical Technology C?
Is BrightGene Bio Medical Technology C stock attractive at the current price?
How is the fair value of 688166 calculated?
Is it still worth investing in stocks now?
What is the share price of BrightGene Bio Medical Technology C (688166)?
What should I pay attention to with BrightGene Bio Medical Technology C right now?
Key figures of BrightGene Bio Medical Technology C
How large is the market capitalisation of BrightGene Bio Medical Technology C (688166)?
What is the P/S ratio of BrightGene Bio Medical Technology C (688166)?
What are the earnings per share of BrightGene Bio Medical Technology C (688166)?
What is the dividend yield of BrightGene Bio Medical Technology C (688166)?
What is the net margin of BrightGene Bio Medical Technology C (688166)?
What is the return on equity of BrightGene Bio Medical Technology C (688166)?
What is the EBIT return on assets of BrightGene Bio Medical Technology C (688166)?
What is the operating margin of BrightGene Bio Medical Technology C (688166)?
How fast is revenue growing at BrightGene Bio Medical Technology C (688166)?
How fast are earnings growing at BrightGene Bio Medical Technology C (688166)?
How much free cash flow does BrightGene Bio Medical Technology C (688166) generate?
How much net debt does BrightGene Bio Medical Technology C (688166) carry?
Watch BrightGene Bio Medical Technology C in the live analysis
One click puts BrightGene Bio Medical Technology C on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.